There can be no assurance that the strategic review of Novartis India Ltd will be completed in 2024, or that the outcome would result in the implementation of any transaction, it said.
Novartis India, a listed entiry, is set to undergo an assessment encompassing various aspects, including its parent Novartis AG s 70.68 percent shareholding.